Prospective randomised double‐blind trial: holmium laser lithotripsy with vs without Moses™ 2.0
Authors:
- Kimberly A. MaciolekKMKimberly A. Maciolek
- Naren NimmagaddaNNNaren Nimmagadda
- Aaron X. LeeALAaron X. Lee
- Ryan S. HsiRHRyan S. Hsi
- Tatsuki KoyamaTKTatsuki Koyama
- Connor M. ForbesCFConnor M. Forbes
- Matthew S. LeeMLMatthew S. Lee
- Cyrus ChehroudiCCCyrus Chehroudi
- Ezra J. MargolinEMEzra J. Margolin
- Ben H. ChewBCBen H. Chew
Open Access
- 13 September 2026
- journal article
- research article
- Published by Wiley in BJU International
- Vol. 138 (6) , 1104-1114
Abstract
Objective: To assess the effect of Moses™ 2.0 (Lumenis Be Ltd., Yokneam Illit, Israel; Boston Scientific, Marlborough, MA, USA) for lithotripsy of renal stones of 8–20 mm in diameter on operative time, surgeon workload, and retropulsion. Subjects/Patients and Methods: In our multicentre, randomised, double‐blind clinical trial, patients were randomised 1:1 to standard or Moses 2.0 laser lithotripsy and stratified by stone size. Patients and surgeons were blinded to laser modality. Primary outcomes were total operative time as well as surgeon workload assessed by the National Aeronautics and Space Administration‐Task Load Index (NASA‐TLX). Secondary outcomes were stone retropulsion evaluated by blinded video review and postoperative clinical outcomes. Linear regression modelling was used for analysis. Results: A total of 153 patients (79 Standard, 74 Moses 2.0) with similar clinical, stone, and operative characteristics were evaluated. There was no significant difference in operative times between the Standard and Moses 2.0 groups ( P = 0.73). Moses 2.0 was associated with lower effort, frustration, mental, physical, and temporal workload, as well as higher rated overall performance compared to the standard laser. Video review demonstrated no difference in rates of retropulsion ( P = 0.13). Complication rates (Standard: 13%; Moses 2.0: 10%) and stone‐free rates (Standard: 51%; Moses: 2.0 55%) were comparable. Conclusion: Our study evaluated the impact of Moses 2.0 technology on high‐powered renal stone dusting, constituting the largest double‐blind trial of its kind to date. There was insufficient evidence to suggest any difference in operative times or clinical outcomes when using Moses 2.0 compared to standard laser lithotripsy. Moses 2.0 was associated with reduced surgeon workload, which has implicit impact on surgeon wellness.Keywords
Funding Information
- Enhancing Diversity in Graduate Education Program
This publication has 24 references indexed in Scilit:
- Indications, preferences, global practice patterns and outcomes in retrograde intrarenal surgery (RIRS) for renal stones in adults: results from a multicenter database of 6669 patients of the global FLEXible ureteroscopy Outcomes Registry (FLEXOR)World Journal of Urology, 2022
- Comparison of stone retropulsion between Moses mode and virtual basket mode: an in vitro study using artificial stonesUrolithiasis, 2022
- Who is hurting? A prospective study of surgeon ergonomicsSurgical Endoscopy, 2021
- Laser Lithotripsy: The Importance of Peak Power and Pulse ModulationEuropean Urology Focus, 2021
- Pulse modulation with Moses technology improves popcorn laser lithotripsyWorld Journal of Urology, 2020
- The REDCap consortium: Building an international community of software platform partnersJournal of Biomedical Informatics, 2019
- Systematic review of measurement tools to assess surgeons' intraoperative cognitive workloadBritish Journal of Surgery, 2018
- Surgical Management of Stones: American Urological Association/Endourological Society Guideline, PART IIJournal of Urology, 2016
- EAU Guidelines on Interventional Treatment for UrolithiasisEuropean Urology, 2016
- Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics supportJournal of Biomedical Informatics, 2009